Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
10.07
-1.10 (-9.81%)
Nov 21, 2024, 3:17 PM EST - Market open
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
50
Market Cap
204.85M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 864.00K | - | - |
| Mar 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ModivCare | 2.79B |
| Inogen | 331.52M |
| Aurora Cannabis | 219.84M |
| LifeMD | 193.06M |
| Zentalis Pharmaceuticals | 40.56M |
| Perspective Therapeutics | 1.56M |
| aTyr Pharma | 235.00K |
CYBN News
- 3 days ago - Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire
- 7 days ago - Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - Business Wire
- 8 days ago - Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - Business Wire
- 21 days ago - Cybin to Participate at the 2024 Milken Institute Future of Health Summit - Business Wire
- 4 weeks ago - Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - Business Wire
- 4 weeks ago - Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor + - Seeking Alpha
- 5 weeks ago - Cybin: Top Value Psychedelic Stock - Seeking Alpha
- 7 weeks ago - Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 - Business Wire